Amryt Pharma Share Discussion Threads

[waterloo01] 12/1/2018 16:59

Good to see 19 centres now active recruiting for EB. The half way point will be interesting as will get a view on how well it's doing. Primary completion date Sept 18, so March for 1st look?

[papillon] 12/1/2018 15:36

Couple of very big buys from late yesterday, but reporting delayed until midday today because of their size. They were for 350k (£71.75k) & 250k (£51.25k) respectively and were both priced at 20.50p. At the time, they were done at the full asking price.
Because of their size they could be institutional trades, but one can't be certain because there are some very wealthy individuals around to whom £70k & £50k is small beer (unfortunately I'm not one of them!).

[papillon] 12/1/2018 14:44

Re the AMYT chart. There was a gap down in September on the placing news (from 25 to 23p) and a gap up in November following on from the Midas tip in the Mail (from circa 17.75 to 19p). Gaps are often "closed" in the short term, but not always. I don't think the gap up of November will now be "closed", but I do expect the gap down of September to be "closed" in the short term. bwtfdik?

[papillon] 12/1/2018 14:28

Hi greendragon. Here's a warning link to any AMYT investors worried about Jacksonpollack's bearish view on the share price The link shows the EDL chart performance since it listed in 2010, taking account of the 20:1 share consolidation in 2016. The chart is abysmal! Don't forget Jacksonpollack is a long term EDL holder. WARNING, those of a squeamish disposition shouldn't open the link! LOL.

[papillon] 12/1/2018 12:51

Volume is increasing now, greendragon. Some decent sized buys going through. Don't take any notice of Jacksonpollack's views, greendragon; nobody else takes any notice of him! I mean anyone who has been stuck in EDL for as long as he has can't be an expert on shares.

He posts that he will buy back into AMYT when the share price is in the low teens again. LOL. The guy is talking out of his ar*e. With the proposed newsflow expected in H1 of this year there is no way that the share price will drop to the low teens. Only the release of bad news will cause that and really bad news could push the share price into single figures.

Jacksonpollack has no patience and doesn't understand how business works. He has the mindset of a short term trader, but he's also sh*t as a short term trader! He got lucky with N4P, but successful traders are not afraid to sell at a loss if they see further falls in a shares share price on the horizon. EDL proves Jp can't bear to sell at a loss to limit further losses. Consequently no experienced share trader will take any notice of Jp's views on AMYT.

[greendragon777] 12/1/2018 12:03

That's fair enough JS, a profit is a profit nothing wrong with that. Take your money and run or forever hold your peace though. we are still invested here and I'm pretty sure everyone here who is still invested are going to see this investment through to the end (or at least the interim trial results).

As Paps said, you may very well get an opportunity to buy in even below the low teens if the results are not in our favour, but until this happens what's the point of you even posting here?

Ooops, sorry about the beeping noise in the background.....that's just an alert going off on my phone that AMYT's share price is going up! :-)

[papillon] 12/1/2018 11:54

"What has Harry done since he's been here"

Probably nothing you idiot! You really are as thick as 2 short planks. He's a NON EXEC Chairman of the Board. He probably only turns up for the Board meetings. The odd day. He's a figurehead; no more, no less. His presence on the BoD no doubt lends an air of gravitas bearing in mind his past CV, but that's about it.

Wiley is the man in charge of the company and for a biopharma AMYT has achieved a lot in the less than two years it has existed.

[jacksonpollack] 12/1/2018 11:30

I sold out at a profit if you'd like to check back. Only ones making money here now are the ever increasing bod's. I mean, come on. What has Harry done since he's been here, lol.

[greendragon777] 12/1/2018 10:01

You're right Jacksonpollock, desperate measures won't turn a share upward, just as selling a share at a loss won't make you any money either, which is what you did I presume?

Good news will turn a share upward though and I believe there will be a string of good news coming from AMYT over the next 5 months in the lead up to the interim trial results (it has already started with the recent announcements) which incidentally I believe will also produce good news (ie- continue the trials as is).

Of course I may be wrong on all of the above but I've put my money where my mouth is and will either pay the price (which I'm fully prepared to do) or reap the reward for doing so.

How about you do the same Jacksonpollock and short the hell outta AMYT because you seem very bearish on it....you could make a lot of money and rub it in our faces while you're at it (double the pleasure!) as I know you'd love the latter even more.

Time will tell though who's made the better call and we don't have all that long to wait before we find out either! 😁

Good luck to JS, you sound like a nice chap who enjoys the prospect of seeing an investor lose some money! I for one hope I can deny you of this gratification on this particular occasion! 😃

[jacksonpollack] 12/1/2018 07:50

You can always tell when confidence is ebbing away from a share when talk turns to top ups. Desperate measures won't turn a share upwards.

[greendragon777] 11/1/2018 23:31

Damn....I better dump my shares Paps, I thought this was a guaranteed trade! 😂😂😂

I've hit about 80% of my top up target so happy as Larry. Should be all set very soon! 👍

Are you all topped up now Paps?

[papillon] 11/1/2018 22:42

Of course the AMYT share price is definitely not guaranteed to breakout upwards from those tight Bollinger Bands, pottermagic. It could breakout from the tight BB's downwards. It could also drift sideways for some time yet. We'll just have to wait and see. It all depends on whether the buyers will outnumber the sellers. I'm bullish on AMYT and wouldn't sell at the current sp, but obviously, for whatever reason, there are still sellers out there who are prepared to sell at the current share price

[pottermagic2310] 11/1/2018 19:25

Ok, thanks for that.

[papillon] 11/1/2018 14:57

"all lines are converging" ????

The Bollinger Bands are converging, pottermagic.

It'll probably need good news to be released for the AMYT share price to breakout upwards, pottermagic, but you never know; if those keen to sell have finished their selling we could see an "uplift" even without the release of further good news in the short term. After all the very recent RNS's have shown that the company is aggresively pushing Lojuxta in new markets with the potential to significantly to increase the revenue (and hence profits) from Lojuxta sales.

AMYT is unusual for a recent biopharma listing on AIM in that it already has a growing revenue stream, in Lojutxa, that was profitable from day one because it was already on sale in certain European markets by the developers of the drug, Novelion (Aegerion). The licensing deal for Lojuxta was an excellent coup for AMYT. It's a good "orphan" drug with good growth prospects that Novelion (which had just acquired the developer of the drug, the loss making Aegerion) preferred to license out rather than develop those markets outside of the America's and Japan itself.

So in conclusion, pottermagic, because of the potential Lojuxta revenue growth and the upcoming AP101 interim phase III EASE trial results (potential blockbuster news for the AMYT sp) we could see an uplift in the AMYT share price in the short term without a further good news RNS. I think that is what the tightening of the Bollinger Bands (they are very tight) and the above average volume is indicating. We shall see. Fingers crossed, as always!

[pottermagic2310] 11/1/2018 14:18

So I there's been a general downward trend but all lines are converging, there's a reasonable chance of an about-turn and significant uplift ?

Useful to know, learn something new everyday... fingers-crossed

[papillon] 11/1/2018 12:24

I agree bazworth. Volume picking up which is a good sign.

[bazworth] 11/1/2018 08:20

A bounce is looking very likely!

[papillon] 10/1/2018 23:05

Log chart. The Bollinger Bands are getting very, very, tight. Breakout coming? Who knows?


free stock charts from uk.advfn.com

[papillon] 10/1/2018 18:27

Good, above average, volume today.

[papillon] 10/1/2018 13:35

"Wouldn't it be nice to be netting around €30m to €40m from Lojuxta by the end of 2018"

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

It would be, greendragon. Perhaps up to 10m Euro's would need to be reimbursed to Novelion in royalty & milestone payments? That could leave up to 30m Euro's based on your upper figure. 5m Euro's to the agents? That would leave 25m Euro's for AMYT. Take 50% (it might be a far higher percentage based on quoted prices for Lojuxta, but hey who knows?) of that figure as profit leaves 12.5m Euro's. Or around £11m. That could justify the current Mkt Cap without any input from AP101?

Are your 2018 revenue figures for Lojuxta are just wishful thinking, greendragon? Probably, but you never know. We'll just have to wait for the figures and AMYT's forecasts for 2018.

[greendragon777] 10/1/2018 11:53

Thanks Paps. I'm an idiot for missing that. I think my eyes were a bit foggy this morning when skimming through the RNS! :-)

Would you care to hazard a guess on the revenue stream potential from these countries? Bear in mind that the prices achieved may be a bit lower in some of those countries. If they could achieve the Swiss prices it could potentially be as high as circa €20m.

Wouldn't it be nice to be netting around €30m to €40m from Lojuxta by the end of 2018......a little ambitious perhaps but nice to fantasize every now and then! haha

[papillon] 10/1/2018 11:27

They mention approximately 100 patients in today's RNS, greendragon and anticipate demand for Lojuxta.

"Amryt estimates that there are approximately 100 patients with HoFH in these countries, with requests for access to Lojuxta made by clinicians throughout the region."

[papillon] 10/1/2018 11:24

Had a very small top up this morning. I've changed my mind on the share price dropping back to 18p, intraday, to fill the gap up that happened in November. The Bollinger Bands are tightening. I don't see the share price dropping much below 20p in the short term, especially as the AP101 interim results are getting closer and the Lojuxta deals keep coming thick and fast.

I think Jacksonpollack is away with the fairies if he thinks this is dropping back to the low teens. He's living in Cloud Cuckoo Land! LOL.